AtaiBeckley surges after report Lilly poised to buy psychedelic drug developer

Eli Lilly is set to acquire the psychedelic drug developer AtaiBeckley in a deal valued at $2.8 billion. Following the report that the pharmaceutical giant is poised to purchase the company, AtaiBeckley shares experienced a significant surge. This strategic acquisition integrates the psychedelic drugmaker into the Eli Lilly portfolio, reflecting a major financial transaction within the pharmaceutical sector as the buyer moves to expand its capabilities in the development of psychedelic medicines.